With a 90% response rate and median progression-free survival approaching four years, taletrectinib is now the preferred frontline treatment for ROS1-positive NSCLC. Its efficacy and manageable safety profile, primarily transient GI toxicity and manageable LFT elevation, surpass older-generation inhibitors.

Despite both Zongertinib and Sevabirtinib showing high efficacy in HER2-mutant NSCLC, Zongertinib's selective nature results in a much better safety profile. Sevabirtinib's dual EGFR/HER2 inhibition leads to significant GI and skin toxicities, making tolerability, not just efficacy, the key factor for clinical preference.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

The RET inhibitor selpercatinib can cause a rare side effect of chylous (milky) ascites or pleural effusion. This can be misread on scans as cancer progression, leading to premature discontinuation of an effective drug. Clinicians must tap the fluid before assuming treatment failure, as switching to pralsetinib may resolve the issue.

While both Talatrectinib and Repotrectinib show impressive efficacy in ROS1-positive NSCLC, the choice between them can hinge on their side effect profiles. Talatrectinib demonstrates lower rates of TRK-related adverse events like dizziness, offering a key advantage in clinical practice.

While tarlatumab causes frequent low-grade side effects like Cytokine Release Syndrome, it results in significantly fewer Grade 3 or higher toxicities compared to standard second-line chemotherapy. This improved safety profile for severe events, particularly a reduction in hematologic toxicities, represents a major quality-of-life advantage for patients with relapsed small cell lung cancer.

Real-world data shows higher rates of cytokine release syndrome (CRS) with tarlatumab than trials reported, especially in sicker patients. Despite this, the drug's risk-benefit profile is often better than chemotherapy for poor-performance patients, sometimes leading to durable, life-changing outcomes where no other options exist.

Selpercatinib can cause a rare but important side effect: chylous (lymphatic fluid) effusions in both the pleural and pericardial spaces. Clinicians must recognize this as a drug-induced toxicity and not misdiagnose it as cancer recurrence, as the condition is manageable with dose interruption or reduction.

Data across multiple studies consistently shows that creating a triplet therapy by adding an antibody to an oral doublet significantly increases the risk of high-grade infections and cytopenias. This makes the two-drug oral combination a safer approach for managing Chronic Lymphocytic Leukemia (CLL).